期刊
EUROPEAN NEUROLOGY
卷 68, 期 3, 页码 137-143出版社
KARGER
DOI: 10.1159/000338774
关键词
Acetylcholinesterase inhibitor; Donepezil; Parkinson's disease; Dementia; Positron emission tomography
资金
- Ministry of Education, Culture, Sports, Science and Technology (MEXT), Japan [18020003]
- Grants-in-Aid for Scientific Research [24390278, 21120007] Funding Source: KAKEN
Background: Although donepezil, an acetylcholinesterase inhibitor, has been proved to be effective in ameliorating cognitive impairment in Parkinson's disease with dementia (PDD), the responsiveness of patients to donepezil therapy varies. [5-C-11-methoxy] donepezil, the radiolabeled form of donepezil, is a ligand for positron emission tomography (PET), which can be exploited for the quantitative analysis of donepezil binding to acetylcholinesterase and for cholinergic imaging. Objectives: To investigate the deficits of the cholinergic system in the brain in PDD and its association with response to donepezil therapy. Methods: Twelve patients with PDD and 13 normal control subjects underwent [5-C-11-methoxy] donepezil-PET imaging. For patients with PDD, daily administration of donepezil was started after [5-C-11-methoxy] donepezil-PET imaging and continued for 3 months. Results: In the PDD group, the mean total distribution volume of the cerebral cortices was 22.7% lower than that of the normal control group. The mean total distribution volume of the patients with PDD was significantly correlated with improvement of visuoperceptual function after 3 months of donepezil therapy. Conclusion: The results suggest that donepezil therapy is more effective in patients with less decrease in acetylcholinesterase, a binding site of donepezil, at least in the specific cognitive domain. Copyright (C) 2012 S. Karger AG, Basel
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据